Faron Pharmaceuticals Oy (FARN)

Currency in GBP
35.00
0.00(0.00%)
Closed·
Trading near 52-week Low
FARN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
34.0036.00
52 wk Range
34.00210.00
Key Statistics
Bid/Ask
34.00 / 38.00
Prev. Close
35
Open
35
Day's Range
34-36
52 wk Range
34-210
Volume
20.16K
Average Volume (3m)
68.25K
1-Year Change
-81.3333%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FARN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1,000.34
Upside
+2,758.12%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Faron Pharmaceuticals Oy News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1,000.34
(+2,758.12% Upside)

Earnings

Latest Release
Aug 27, 2025
EPS / Forecast
-0.18 / -0.13
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FARN Income Statement

Compare FARN to Peers and Sector

Metrics to compare
FARN
Peers
Sector
Relationship
P/E Ratio
−5.2x−4.3x−0.4x
PEG Ratio
−0.090.010.00
Price/Book
7.3x1.1x2.6x
Price / LTM Sales
-15.3x3.0x
Upside (Analyst Target)
-218.5%54.5%
Fair Value Upside
Unlock0.6%7.2%Unlock

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.98M1.44%1.04M
Other Institutional Investors
38.13M18.46%13.35M
Public Companies & Retail Investors
165.43M80.09%57.90M
Total
206.54M100.00%72.29M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Heights Capital Management, Inc.9.87%20,394,7967,138
Blood Cancer United, Inc.3.41%7,037,4262,463

People Also Watch

149.40
GBGP
-4.48%
143.60
CURY
-2.97%
201.00
TRNT
-1.76%
166.40
CAML
0.00%
1,399.00
JET2
-1.69%

FAQ

What Is the Faron Pharmaceuticals Oy (FARN) Stock Price Today?

The Faron Pharmaceuticals Oy stock price today is 35.00 GBP.

What Stock Exchange Does Faron Pharmaceuticals Oy Trade On?

Faron Pharmaceuticals Oy is listed and trades on the London Stock Exchange.

What Is the Stock Symbol for Faron Pharmaceuticals Oy?

The stock symbol for Faron Pharmaceuticals Oy is "FARN."

What Is the Faron Pharmaceuticals Oy Market Cap?

As of today, Faron Pharmaceuticals Oy market cap is 72.29M GBP.

What Is Faron Pharmaceuticals Oy's Earnings Per Share (TTM)?

The Faron Pharmaceuticals Oy EPS (TTM) is -0.12.

From a Technical Analysis Perspective, Is FARN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Faron Pharmaceuticals Oy Stock Split?

Faron Pharmaceuticals Oy has split 1 times.

How Many Employees Does Faron Pharmaceuticals Oy Have?

Faron Pharmaceuticals Oy has 36 employees.

What is the current trading status of Faron Pharmaceuticals Oy (FARN)?

As of Sep 20, 2026, Faron Pharmaceuticals Oy (FARN) is trading at a price of 35.00 GBP, with a previous close of 35.00 GBP. The stock has fluctuated within a day range of 34.00 GBP to 36.00 GBP, while its 52-week range spans from 34.00 GBP to 210.00 GBP.

What Is Faron Pharmaceuticals Oy (FARN) Price Target According to Analysts?

The average 12-month price target for Faron Pharmaceuticals Oy is 1,000.34 GBP, with a high estimate of 1000.34302375 GBP and a low estimate of 1000.34302375 GBP. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +2,758.12% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.